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ABSTRACT
Organophosphates have a long history of use as insecticides over the world. The aim of the present study was to investigate
the interethnic differences in kinetics, biomarker formation, and in vivo red blood cell acetylcholinesterase inhibition of
chlorpyrifos (CPF) in the Chinese and the Caucasian population. To this purpose, physiologically based kinetic models for
CPF in both the Chinese and Caucasian population were developed, and used to study time- and dose-dependent
interethnic variation in urinary biomarkers and to convert concentration-response curves for red blood cell
acetylcholinesterase inhibition to in vivo dose-response curves in these 2 populations by reverse dosimetry. The results
obtained revealed a marked interethnic difference in toxicokinetics of CPF, with lower urinary biomarker levels at similar
dose levels and slower CPF bioactivation and faster chlorpyrifos-oxon detoxification in the Chinese compared with the
Caucasian population, resulting in 5- to 6-fold higher CPF sensitivity of the Caucasian than the Chinese population. These
differences might be related to variation in the frequency of single-nucleotide polymorphisms for the major
biotransformation enzymes involved. To conclude, the interethnic variation in kinetics of CPF may affect both its
biomarker-based exposure assessment and its toxicity and risk assessment and physiologically based kinetic modeling
facilitates the characterization and quantification of these interethnic variations.
Key words: organophosphate pesticide; chlorpyrifos; interethnic variation; physiologically based kinetic modeling; reverse
dosimetry; acetylcholinesterase inhibition.
Organophosphate pesticides (OPs) are an important class of
crop protection agents used worldwide (Stauber et al., 2016). OPs
and their metabolites have been detected in human urine,
blood, serum, and breast milk (Drevenkar et al., 1994; Hardt and
Angerer, 2000; Liu et al., 2014; Naksen et al., 2016; Zhang et al.,
2014), reflecting human exposure to these pesticides. Upon
acute exposure, the activated form of OPs can covalently bind to
and inhibit acetylcholinesterase (AChE), the enzyme responsi-
ble for hydrolysis of the neurotransmitter acetylcholine (ACh)
(Flaskos, 2014). This inhibition causes accumulation of ACh in
the synaptic cleft, resulting in overstimulation of the ACh recep-
tor ultimately causing cholinergic dysfunction, paralysis, and
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respiratory failure (Eaton et al., 2008; Hung et al., 2015). Chronic
low dose exposure to OPs has been associated with poorer neu-
robehavioral development in infants/school children and poorer
intellectual development in 7-year-old children (Bouchard et al.,
2011; Gonzalez-Alzaga et al., 2014; Wang et al., 2012).
In the past decades, physiologically based kinetic (PBK) mod-
els have been developed for a few OPs, i.e. chlorpyrifos (CPF)
(Bouchard et al., 2005; Lu et al., 2009; Mosquin et al., 2009;
Timchalk et al., 2002) and diazinon (Poet et al., 2004), in order to
better predict the internal exposure level and risk upon expo-
sure to OPs (Bouchard et al., 2005; Foxenberg et al., 2011; Lu et al.,
2009; Mosquin et al., 2009; Nolan et al., 1984; Timchalk et al.,
2002). These PBK models can be used for reverse dosimetry, en-
abling translation of urinary biomarker data to internal or exter-
nal exposure levels, whereas in theory, also enabling
conversion of in vitro concentration-response curves for AChE
inhibition to in vivo dose-response curves for AChE inhibition.
However, when developing these PBK models, interethnic dif-
ferences have not yet been taken into account. Biomonitoring
studies have reported OP metabolite levels in maternal urine in
China to be higher than those in maternal urine in developed
countries (Wang et al., 2012), and interethnic differences in bio-
activation and detoxification have already been reported for
other compounds than OPs (Ning et al., 2017; Zhang et al., 1990).
Hence, it is of importance to include the interethnic differences
in kinetics when developing PBK models for CPF in human. To
date, several PBK models have been developed for CPF in the
Caucasian population (Bouchard et al., 2005; Lu et al., 2009;
Mosquin et al., 2009; Timchalk et al., 2002). Knowing that there is
no PBK model available that is specifically defined for the
Chinese population, the aim of the present study was to investi-
gate, via PBK modeling, the interethnic differences between the
Chinese and the Caucasian population in kinetics, biomarkers
of exposure, and predicted in vivo red blood cell (RBC) AChE inhi-
bition using CPF as the model OP compound.
In present study, CPF was used as model OP because there
are available kinetic data for evaluating the performance of the
PBK models (Eaton et al., 2008; Griffin et al., 1999; Nolan et al.,
1984; Brzak et al., 2000; Timchalk et al., 2002; Bouchard et al.,
2005). In humans, CPF will be either detoxified to 3,5,6-trichloro-
2-pyridinol (TCPy) and diethyl thiophosphate (DETP) or acti-
vated to the corresponding active oxon form chlorpyrifos-oxon
(CPO), which inhibits AChE (Figure 1). These 2 pathways have
been demonstrated to occur mainly in the liver (Timchalk et al.,
2002). Conversion of CPF is catalyzed by cytochromes P450
(CYP450), with CYP2B6 being the most active CYP450 for conver-
sion of CPF into CPO, and CYP2C19 being the most active CYP
for conversion of CPF into TCPy and DETP, whereas CYP3A4 is
involved in both pathways (Foxenberg et al., 2007; Tang et al.,
2001). The detoxification of CPO is catalyzed by A-esterases,
with paraoxonase (PON 1) as the major A-esterase involved,
resulting in formation of TCPy and diethyl phosphate (DEP)
(Figure 1) (Furlong et al., 1989; Timchalk et al., 2002). B-esterase
in for example liver, blood, and brain including AChE, butyryl-
cholinesterase (BChE) and carboxylesterase (CaE) can be bound
and inhibited by CPO (Timchalk et al., 2002; Wagner, 1999).
The inhibition of RBC AChE activity has been used as the
surrogate endpoint for deriving points of departure (POD) in risk
assessment of CPF, such as a benchmark dose (BMD) or a no ob-
served adverse effect level (NOAEL). The rationale for using RBC
AChE inhibition as indicator of CPF exposure is based on the
fact that RBC AChE is more sensitive and easier to sample com-
pared with AChE in other target organs like brain, spinal cord,
and the peripheral nervous system (EPA, 2011). Moreover, it is
also known that there is less variation among individuals in the
enzyme activity of RBC AChE than plasma BChE (Brock and
Brock, 1990; Lefkowitz et al., 2007). Thus, in the present study,
the concentration-dependent RBC AChE inhibition by CPO (Eyer
et al., 2009) was used as the surrogate endpoint to define the
in vivo dose-response curves for RBC AChE inhibition in the 2
populations, Chinese and Caucasian, upon CPF exposure.
MATERIALS ANDMETHODS
Materials
Chemicals. Chlorpyrifos and TCPy were purchased from Sigma-
Aldrich (Zwijndrecht, The Netherlands). Chlorpyrifos-oxon was
purchased from TRC-Canada (Toronto, Ontario, Canada).
Tetraisopropyl pyrophosphoramide (iso-OMPA) and diisopropyl
ether (DIPE) were purchased from Sigma-Aldrich (Zwijndrecht,
The Netherlands). Magnesium chloride hexahydrate
(MgCl2*6H2O), ethylenediaminetetraacetic acid disodium salt
dihydrate (EDTA), dipotassium hydrogen phosphate (K2HPO4),
trifluoroacetic acid (TFA), hydrochloric acid (HCl), perchloric
acid (HClO4), dimethylsulfoxide (DMSO), and calcium chloride
dihydrate (CaCl2*2H2O) were purchased from VWR International
(Amsterdam, The Netherlands). Acetonitrile (ACN, UPLC/MS
grade) and methanol (UPLC/MS grade) were purchased from
Biosolve (Valkenswaard, The Netherlands). Reduced nicotin-
amide adenine dinucleotide phosphate (NADPH) was obtained
from Sigma-Aldrich (Zwijndrecht, The Netherlands).
Human liver microsomes. Caucasian liver microsomes (pooled
from 20 donors, mixed gender) were purchased from Corning
(Amsterdam, The Netherlands) and Chinese liver microsomes
(pooled from 20 donors, mixed gender) were purchased from
Pre-TOX (Wuhan, China).
In Vitro Incubations to Derive the Kinetic Parameters for the PBK
Model
Human liver microsomal incubations for bioactivation and de-
toxification of CPF by CYP450 were optimized to be linear in me-
tabolite formation with time and amount of microsomal protein
(data not shown). The incubations were carried out in 50 mM
phosphate buffer (pH 7.4) containing (final concentrations)
5 mM MgCl2, 1 mM EDTA (A-esterase PON1 inhibitor), 50 mM iso-
OMPA (B-esterase inhibitor), 1 mM NADPH (CYP450 cofactor),
and CPF (at final concentrations ranging from 5 to 100 mM, added
from 100 times concentrated stock solutions in DMSO). Control
incubations were performed without the addition of NADPH.
After 1 min preincubation, the reaction was initiated by adding
5 ml of either Caucasian or Chinese liver microsomes (final con-
centration 0.5 mg/ml) and incubated for 15 min (Caucasian) or
30 min (Chinese) in a 37C water bath. The total volume of the
incubation mixtures was 200 ml. The reaction was terminated by
the addition of 20 ml ice cold 10% (vol/vol) HClO4.
The PON1-catalyzed metabolism of CPO was measured in
the in vitro liver microsomal incubations as follows. Preliminary
experiments were conducted to define the optimal incubation
conditions that are linear in time and with the liver microsomal
concentration (data not shown). The kinetic incubations were
carried out in 50 mM Tris–HCl (pH 7.4) containing 2 mM CaCl2 (to
stimulate the PON1 activity) (Carr et al., 2015), and CPO (at a final
concentration range of 25–1500 mM, added from 100 times con-
centrated stock solutions in DMSO). After 1 min preincubation,
the reaction was initiated by adding either 5 ml of Caucasian (fi-
nal concentration 0.5 mg/ml) or 2.5 ml of Chinese liver
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microsomes (final concentration 0.25 mg/ml) and incubated for
5 min in a 37C water bath. Incubations in the absence of micro-
somes were performed as control. The total volume of the incu-
bation mixtures was 200 ml. The reaction was terminated by the
addition of 20 ml ice cold 10% (vol/vol) HClO4 and samples were
kept on ice.
Extraction of metabolites was conducted prior to UPLC anal-
ysis. To this end, the organic solvent DIPE was added to the ice-
cold incubation mixtures. Afterwards, the incubation mixtures
were mixed well by vortexing and the upper layer that con-
tained CPF and its metabolites was collected and transferred
into a glass tube. The extraction process was conducted 3 times,
and the collected DIPE fractions were combined. The extracts
were then evaporated to dryness under a stream of nitrogen
(N2). Finally, the extracts containing CPF and its metabolites
were redissolved in 100 ml methanol and subsequently used for
the UPLC analysis.
It is worth to note that microsomal incubations are well ac-
cepted and also validated to define kinetic parameters for me-
tabolism and clearance in PBK modeling (Al-Subeihi et al., 2012;
Lu et al., 2009; Mosquin et al., 2009; Ning et al., 2017; Punt et al.,
2008, 2009; Timchalk et al., 2002). Furthermore experimental
data shown that kinetic data derived from microsomal incuba-
tions and hepatocyte incubations are comparable as Di et al.
(2012) reported that the intrinsic clearance for compounds pre-
dominantly mediated by CYP450 obtained from microsomal
incubations are comparable with that obtained from hepatocyte
incubations.
UPLC Analysis
All redissolved extracts from microsomal incubations of CPF
were analyzed by a Waters Acquity UPLC H_class system that
consisted of a quaternary solvent manager, a sample manager,
and a photodiode array detector, equipped with a Water
Acquity UPLC BEH C18 column (1.7 lm, 2.1 50 mm) and Waters
Xbridge UPLC BEH C18 precolumn (2.5 mM, 2.1 5 mm). The tem-
perature of the column was set at 40C and the auto-sampler at
10C during the UPLC analysis. The mobile phases used for the
analysis consisted of (A) 0.1% TFA in nanopure water and (B)
100% ACN. A gradient elution at a flow rate of 0.6 ml/min was
applied for the analysis with the initial condition of 90% A:10%
B (vol/vol). The gradient program was set as follows: the starting
condition was 90:10 (A:B), changing to 0:100 (A:B) from 0 to
6 min and was maintained for 30 s, and then changed to 100:0
(A:B) in 30 s and was maintained for 1 min. After which, the
starting condition were reset from 8 to 8.1 min, and the column
was equilibrated at the starting condition of 90:10 (A:B) until
9.5 min. The injection volume for each sample was 3.5 ml. Under
these conditions, the retention times of CPF, CPO, and TCPy
were 4.8, 3.6, and 2.5 min, respectively. The amount of CPF, CPO,
and TCPy was quantified by integrating the peak areas at
299 nm using calibration curves that were prepared using the
commercially available standards.
Data Analysis
Kinetic parameters including the apparent maximum velocity
(Vmax; expressed in nmol/min/mg microsomal protein) and the
apparent Michaelis–Menten constant (Km; in mM) for bioactiva-
tion of CPF and detoxification of CPF and CPO were obtained by
fitting the data using GraphPad Prism 5 software for Windows,
version 5.04 (San Diego, California) to the standard Michaelis–
Menten equation:
Figure 1. Metabolic pathways for bioactivation and detoxification of CPF (Smith et al., 2011). AChE, acetylcholinesterase; CYP450, cytochrome P450.
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V ¼ Vmax  ½S=ðKm þ ½SÞ
in which the S represents the concentration of substrate in mM.
Physiologically based kinetic (PBK) model
Model structure. Figure 2 illustrates the structure of the CPF PBK
model for both the Chinese and Caucasian population. The
model was developed based on the model reported by Timchalk
et al. (2002) with some modifications. The model contained sep-
arated compartments for the gastrointestinal tract (GI-tract),
blood, fat, liver, slowly perfused tissue (muscle, skin, and bone),
and rapidly perfused tissue. The bioavailability of CPF upon oral
exposure was included by taking the fractional absorption (fa)
into account. This fa was found to vary across human volunteer
studies, amounting to 0.22 (22% of the oral dose being absorbed)
(Bouchard et al., 2005), 0.224 (Timchalk et al., 2002), 0.70 (Nolan
et al., 1984), and 0.93 (Bouchard et al., 2005; Griffin et al., 1999), re-
spectively, in part depending on the form of CPF administration
(Timchalk et al., 2002). When modeling the data, the fa values
reported by Timchalk et al. (2002; fa¼ 0.224) and Nolan et al.
(1984; fa¼ 0.70) were used, and the mean of those 2 fa values,
which is 0.462, was also included. First-order kinetics was used
to describe the absorption of CPF by the GI tract with an absorp-
tion rate constant of 0.46/h (Bouchard et al., 2005). The absorbed
CPF was assumed to be transferred to the liver compartment
without intestinal biotransformation based on the fact that in-
testinal CPF biotransformation was reported to be limited com-
pared with that in the liver (Leoni et al., 2012). Furthermore,
CYP450-mediated conversion of CPF was assumed to occur only
in the liver because liver is known to be the main organ for
CYP450-mediated biotransformation of CPF (Leoni et al., 2012).
This metabolism resulted in formation of TCPy and DETP, and
of CPO (Figure 1). Based on a preliminary experiment (data not
shown), the conversion of CPF by A-esterase (PON1) appeared to
be negligible compared with the CYP450-catalyzed reaction and
thus was not included in the model. The PBK model also con-
tained a sub-model describing the kinetics of CPO. The forma-
tion of CPO from CYP450-mediated conversion of CPF in the
liver compartment provided the input of CPO for this CPO sub-
model, in which CPO was predicted to be further converted to
TCPy and DEP in both the liver and blood compartment medi-
ated by A-esterase (PON1). The cumulative urinary excretion of
TCPy and of the dialkylphosphate (defined as the sum of DEP
and DETP) was described by applying first-order rate equations
with the first-order rate constants amounting to 0.026/h and
0.199/h, respectively (Bouchard et al., 2005). The Rosenbrock’s al-
gorithm for stiff systems was used to code the differential equa-
tions and the mass balance in Berkeley Madonna software
(Macey and Oster, UC Berkeley, California). The PBK model dif-
ferential equations are provided in the Supplementary Data I.
Model parameters. The physiological parameters for both the
Chinese and Caucasian population were collected from the lit-
erature (Brown et al., 1997; NHFPC, 2007a,b, 2014) and are pre-
sented in Table 1. The physico-chemical parameters
(tissue:blood partition coefficients) for CPF and CPO, also pre-
sented in Table 1, were determined based on clogP using
ChemDraw Professional 16.0 software (CambrigeSoft), using the
method described by DeJongh et al. (1997). The kinetic parame-
ters for conversion of CPF and CPO in the liver were determined
in the present study and are summarized in Table 2 and pre-
sented in some more details in the Results section. For PON1-
mediated detoxification of CPO to TCPy in blood, the Vmax
expressed in mmol/h/kg bw0.75 for the Caucasian population,
obtained from plasma enzymatic incubations (Furlong et al.,
1989; Mosquin et al., 2009), was multiplied by the bw0.75 of the
Chinese and Caucasian, respectively, to obtain the correspond-
ing value for both populations expressed in mmol/h. A hepatic
microsomal protein scaling factor of 32 mg microsomal protein/
g liver (Al-Malahmeh et al., 2017; Barter et al., 2007) was applied
to scale the apparent Vmaxc from mmol/min/mg microsomal pro-
tein to the Vmax expressed in mmol/min/g liver. Furthermore,
the Vmax was expressed in mmol/h/kg liver.
Model validation. To validate the model, the PBK model-predicted
blood concentration of TCPy and the cumulative urinary
amount of TCPy were compared with reported in vivo data
(Bouchard et al., 2005; Nolan et al., 1984; Timchalk et al., 2002).
Sensitivity analysis. The impact of each parameter on the model
output (in this study especially the blood concentrations of CPO)
was estimated by performing a sensitivity analysis. Normalized
sensitivity coefficient (SC) was determined based on the follow-
ing equation:
SC ¼ ðC0  CÞ=ðP0  PÞ  ðP=CÞ
in which P represents the parameter value in the PBK model
and P0 represents the parameter value with a 5% increase (Evans
and Andersen, 2000). Similarly, C is the output of the model
with the original model parameter value and C0 the model out-
put with 5% increase in the model parameter value. Only
parameters with SC> 0.15 (absolute value) are presented in the
current manuscript (Figure 7).
Reverse Dosimetry
Derivation of a concentration-response curve for RBC AChE inhibition.
In the present study, the concentration-response curve for CPO-
mediated RBC AChE inhibition reported by Eyer et al. (2009) was
used, who quantified the level of AChE inhibition upon incubat-
ing plasma samples from CPF-poisoned patients (with quanti-
fied level of CPO) with hemolysate from an unexposed donor to
determine the level of AChE inhibition (Eyer et al., 2009).
Conversion of concentration-response curves to in vivo dose-response
curves for RBC AChE inhibition. The concentration-response curve
for RBC AChE inhibition by CPO in human was obtained from
Eyer et al. (2009), and used as input to quantify the maximum
blood concentration (Cmax) of CPO in the PBK models for calcu-
lating the corresponding dose levels. By performing this calcula-
tion for all the concentrations, the concentration-response
curve for RBC AChE inhibition was converted to an in vivo dose-
response curve for CPF-induced RBC AChE inhibition. Given that
the concentrations in the concentration-response curve repre-
sented the total concentration of CPO (Eyer et al., 2009; Heilmair
et al., 2008), the concentration values of the concentration-
response curve could be directly used as input in the PBK mod-
els. By performing the reverse dosimetry using the PBK model
for the Caucasian and Chinese population, in vivo dose-
response curves for both ethnic groups were predicted.
Validation of predicted dose-response curves for RBC AChE inhibition.
To validate the performance of the PBK model-facilitated re-
verse dosimetry approach, the predicted dose-response curve
for RBC AChE inhibition upon exposure to CPF for the Caucasian
population was compared with available in vivo data (EPA, 1999;
Timchalk et al., 2002). Evaluation of the Chinese PBK model was
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based on the evaluation of the Caucasian model combined with
the fact that both models were defined in the same way.
Derivation of BMD and BMDL
The predicted dose-response curves were used to derive PODs
for CPF risk assessment for these 2 populations. Because the
data were not suitable for BMD modeling, the effective dose
(ED)10/20 value for CPF in the Chinese and Caucasian was defined
at 10% or 20% inhibition of RBC AChE. Subsequently, taking into
account that a BMDL should not be more than a factor 3 below a
BMD value to provide an adequate POD, the obtained ED10/20 val-
ues were divided by 3 to obtain POD values that could be com-
pared with the PODs reported by The European Food Safety
Authority (EFSA, 2014) and EPA (BfR, 2012; Fan, 2014;
Koshlukova and Reed, 2014).
RESULTS
In VitroMetabolism of CPF and CPO
The CYP450-mediated conversion of CPF to CPO and TCPy was
measured in incubations with both Chinese and Caucasian liver
microsomes. No metabolites were detected in control incuba-
tion performed in the absence of NADPH. The PON1-mediated
conversion of CPO to TCPy was detected in both population,
Chinese and Caucasian, of liver microsomal incubations,
whereas in the absence of liver microsomes, some TCPy was
detected, mainly ascribed to an impurity in the CPO starting
material (data not shown). Thus, results obtained in the pres-
ence of liver microsomes were corrected for the TCPy detected
in control incubation without microsomes.
The concentration-dependent increase in metabolite forma-
tion following incubations of CPF and CPO with both Chinese
and Caucasian liver microsomes is depicted in Figure 3. The ki-
netic parameters Km and Vmax derived from these results as
well as the catalytic efficiency, calculated as Vmax/Km, are pre-
sented in Table 2.
The results presented in Figure 3 and Table 2 indicate that
there is a difference in the catalytic efficiency for conversion of
CPF and CPO by the Chinese and Caucasian population. The cat-
alytic efficiency for bioactivation of CPF to CPO was around 4.5-
fold less efficient in incubations with Chinese than with
Caucasian liver microsomes, due to a 2.8-fold lower Vmax and a
1.6-fold higher Km (Table 2). However, Chinese liver microsomes
were only 2 times less efficient than Caucasian liver micro-
somes in detoxification of CPF to TCPy. In addition, Chinese
liver microsomes appeared to be 2.8 times more efficient in the
detoxification of CPO into TCPy than Caucasian liver
microsomes.
PBK Model Validation
The developed PBK model of CPF was evaluated against in vivo
data from human volunteer studies in the Caucasian population
(Bouchard et al., 2005; Nolan et al., 1984; Timchalk et al., 2002).
The model was first evaluated using the data from Nolan et al.
(1984). Figure 4A presents the model-predicted and reported
amount of TCPy eliminated in urine using an fa of 0.70, as
reported by Nolan et al. (1984). In addition, Figure 4B compares
the model-predicted blood concentration of TCPy and the
reported data. These results indicate that the predictions made
by the newly developed PBK model match the reported data
Figure 2. Schematic diagram of the PBK model for CPF (Timchalk et al., 2002) in the Chinese and Caucasian population, consisting of 2 models including one for CPF
(left) and one submodel for CPO (right). GI tract, gastrointestinal tract.
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quite well, and in a manner comparable with the model
reported before by Lu et al. (2009). However, a best fit between
model-predicted TCPy blood concentration and in vivo data
could be achieved (Figure 4) by increasing the volume of distri-
bution for TCPy (Vd) from 5.53 l (setting the Vd equal to the aver-
age human blood volume (VB; Brown et al., 1997)) to 15 l. This
15 l was obtained by fitting the model to in vivo data (Nolan et al.,
1984) similar as done by others (Mosquin et al., 2009; Timchalk
et al. 2002). Together these data illustrate how the currently de-
veloped PBK model can adequately match the reported in vivo
data.
In a next step, a comparison was made to the data reported
by Timchalk et al. (2002) and Lu et al. (2009) to further evaluate
the developed-PBK model (Figure 5). The application of
fa¼ 0.224, as reported by this literature, was set in the defined
PBK model for the Caucasian population, resulting in a good
match between predicted and experimental human in vivo data
(Lu et al., 2009; Timchalk et al., 2002). Also, the model adequately
predicted the blood concentration of TCPy with 3-fold deviation
from the data reported by Timchalk et al. (2002). Using a Vd of
15 l, fitting this model parameter Vd to the in vivo data as done
by Timchalk et al. (2002) and Mosquin et al. (2009), a better fit
was even obtained (see Figure 5).
Finally, the performance of the model was evaluated based
on the experimental data originally from Brzak (2000) but
reported by Bouchard et al. (2005) using an fa of 0.22 (Bouchard
et al., 2005) (Figure 6). The results reveal that also for this data
set, the newly developed PBK model closely predicted both the
cumulative amount of TCPy eliminated in urine and the blood
concentration of TCPy at all 3 dose levels tested. The predicted
TCPy concentration in blood were around 3-fold higher than
what was actually observed in vivo. As observed from the other
data sets, these matches could be further improved by changing
the value of Vd to 15 l, based on fitting this model parameter to
the in vivo data as done by others (Mosquin et al., 2009; Timchalk
et al. 2002) (see Figure 6).
Although some underestimation is still observed at later
time points after reaching the maximum TCPy blood concentra-
tion when comparing our prediction with the in vivo data from
Timchalk et al. (2002) as well as with the data from Brzak (2000)
after changing the Vd to 15 l. These inter-study differences are
mainly caused by the TCPy elimination rate constant (Ke) that
we used because the value of Ke (0.026/h) that we used in our
model was obtained from Nolan et al. (1984) but not obtained by
fitting model to data from Nolan et al. (1984) as what others did
(Ke¼ 0.017/h in Timchalk et al., 2002 and Ke¼ 0.03820/h in
Mosquin et al., 2009). Thus, these fits can be improved even fur-
ther if we fit Ke (0.019/h) in the model to in vivo data Nolan et al.
(1984) in line with what others did (Mosquin et al., 2009;
Timchalk et al., 2002) (Supplementary Data V and VI).
In our later prediction, we assumed the Vd for TCPy to be
equal to human blood volume (5.53 l, Brown et al., 1997), which
has physiological meaning, and Ke equal to 0.026/h.
Nevertheless, a better match between the model prediction and
in vivo data for the blood concentration of TCPy could be
obtained when the Vd value was increased to 15 l. The match
between the model prediction and in vivo data sets from
Timchalk et al. (2002) and Brzak (2000) can be further improved
by changing Ke to 0.019/h (both of these 2 parameters were
obtained by fitting the model to the in vivo data Nolan et al.
(1984) as done by others (Mosquin et al., 2009; Timchalk et al.
2002). However, it is important to note as well that changing the
value of Vd and value of Ke did not affect the prediction of the
CPO concentration in blood, and thus also did not affect the
resulting prediction for AChE inhibition (data not shown).
Due to a lack of kinetic data for Chinese subjects, evaluation
of the performance of the PBK model for CPF in the Chinese
population was based on this validation of the Caucasian
model.
Sensitivity Analysis
A sensitivity analysis was performed at a dose of 0.5 mg CPF/kg
bw and of 180 mg CPF/kg bw (Timchalk et al., 2002) to determine
the impact of each parameter on the predicted blood Cmax of
CPO in the Chinese and the Caucasian PBK models. Figure 7
presents the values for which the SC was higher than 0.15 (abso-
lute value). Comparing the results of the sensitivity analysis for
the Chinese PBK model with that of the Caucasian PBK model, a
similar result was obtained at both dose levels. For both the
Chinese and the Caucasian model, the prediction of the Cmax of
CPO appeared to be mainly affected by the kinetic parameters
for hepatic CPO formation as well as the kinetic parameters for
hepatic detoxification of CPO to TCPy, although the fa also sig-
nificantly affected the Cmax of CPO (Figure 7A). In addition, the
Cmax of CPO was also influenced by blood flow from various
compartments (liver to blood, rapidly perfused tissue to blood
and slowly perfused tissue to blood). For physiological parame-
ters, volume of liver was found to have the largest impact in
both the Caucasian and the Chinese model. At the higher dose
of 180 mg/kg bw, similar results were obtained except for a
somewhat lower impact of the kinetic parameters for conver-
sion of CPF to TCPy.
Table 1. Summary of Physiological and Physicochemical Parameters
for the PBK Models for CPF and Its Metabolites in the Caucasian and
Chinese population (Brown et al., 1997; DeJongh et al., 1997; NHFPC,
2007a,b, 2014)
Model parameters Caucasian Chinese
Physiological parameters
Body weight (kg) 70 58.5
Percentage of body weight
Liver 2.6 2.3
Fat 21.4 18.4
Rapidly perfused 5.4 6.9
Slowly perfused 58 57.3
Blood 7.9 7.9
Flow(l/h)
Cardiac output 347.9 327
Percentage of cardiac output
Liver 22.7 26.3
Fat 5.2 6.8
Rapidly perfused 43 42.4
Slowly perfused 29.1 24.5
Tissue: blood partition coefficients for CPF
Liver 8.1 8.1
Fat 142 142
Rapidly perfused 8.1 8.1
Slowly perfused 5.2 5.2
Tissue: blood partition coefficients for CPO
Liver 4.9 4.9
Fat 119.3 119.3
Rapidly perfused 4.9 4.9
Slowly perfused 3.3 3.3
The kinetic parameters for the PBK models are presented in Table 2.
Abbreviations: PBK, physiologically based kinetic; CPF, chlorpyrifos; CPO, chlor-
pyrifos-oxon.
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PBK Model Predictions
Dose-dependent blood concentrations of CPO. After PBK model vali-
dation, the defined models were used to quantify the dose-
dependent blood Cmax of CPO in both populations using not
only fa¼ 0.224 (Figure 8A) but also fa¼ 0.462 and fa¼ 0.70 (pre-
sented in Supplementary Data II) in order to take into account
the different values reported in the literature of CPF bioavail-
ability. Comparison of the blood Cmax of CPO at increasing dose
levels in the Chinese and the Caucasian population, reveals a 5-
to 8-fold difference in the Cmax values between the Caucasian
and the Chinese population, with the Cmax values for the
Caucasian population being higher (Figure 8A). This difference
originates from the less efficient bioactivation of CFP to CPO
and the more efficient detoxification of CPO in the Chinese as
compared with the Caucasian population, which already noted
above. Clearly, the PBK model integrates the kinetic data for the
individual reactions enabling prediction of the overall effect on
the Cmax for CPO.
Time- and dose-dependent cumulative urinary excretion of TCPy. The
defined PBK models were also used to predict the time- and
dose-dependent cumulative urinary excretion of TCPy in both
ethnic groups, in order to capture the possible ethnic differen-
ces when using urinary TCPy as a biomarker for exposure as-
sessment. The time-dependent cumulative excretion was
predicted to increase especially over the first 72 h. The time-
dependent urinary TCPy excretion at a dose level of 0.5 mg/kg
was predicted to be 1- to 2-fold higher in the Caucasian than in
the Chinese population, and a similar pattern was observed at a
higher CPF dose of 180 mg/kg bw (data for fa¼ 0.224 presented
in Figs. 8B and 8C, data for fa¼ 0.46 and fa¼ 0.70 presented in
Supplementary Data II). The CPF dose-dependent urinary excre-
tion of TCPy (data for fa¼ 0.224 are presented in Figure 8D, data
for fa¼ 0.46 and fa¼ 0.70 are presented in Supplementary Data
II) reveals a difference in urinary TCPy levels at similar dose lev-
els at both 24 and 72 h, with the levels in Caucasians being
higher than those in Chinese (Figure 8D). The curves also indi-
cate that to reach a similar urinary TCPy elimination as in the
Caucasian, the corresponding dose level of CPF exposure may
vary from 1.3- to 5-fold higher in the Chinese, depending on the
duration for urinary collection, the CPF dose and the fa
(Figure 8D).
Interethnic differences in CPF dose-dependent inhibition of AChE. In a
next step, the CPO concentration-dependent AChE inhibition
curve reported by Eyer et al. (2009) was converted into CPF dose-
dependent curves for AChE inhibition in the Caucasian and
Chinese population using PBK model-facilitated reverse dosim-
etry to calculate the dose levels required to generate the respec-
tive CPO Cmax values. Figure 9 presents the predicted in vivo
dose-response curves for CPF-mediated AChE inhibition in the
Caucasian and Chinese population using the 3 different values
Table 2. Summary of Kinetic Parameters (Km, unscaled/scaled Vmax) and Catalytic Efficiency (Vmax/Km), for Metabolism of CPF and CPO (Barter
et al., 2007; Brown et al., 1997; Furlong et al., 1989; Mosquin et al., 2009; NHFPC, 2007a)
Ethnic Pathway Caucasian Chinese
CPF to CPO (Liver)
Km1 (mM) 28.59 6 6.60 44.916 34.90
In vitro Vmax1c (nmol / min / mg microsomal protein) 0.156 6 0.014 0.055 6 0.019
In vitro Catalytic efficiency (Vmax1c / Km1 )
ab 5.5 1.2
In vivo scaled Vmax1 (mmol / h / kg liver)
c 300 6 27 106 6 36
In vivo scaled Catalytic efficiency (Vmax1 / Km1 )
d 10.49 2.36
CPF to TCPy (Liver)
Km2 (mM) 4.33 6 0.56 3.16 6 0.745
In vitro Vmax2c (nmol / min / mg microsomal protein) 0.234 6 0.006 0.093 6 0.004
In vitro Catalytic efficiency (Vmax2c / Km2 )
ab 54.0 29.4
In vivo scaled Vmax2 (mmol / h / kg liver)
c 449 6 12 179 6 8
In vivo scaled Catalytic efficiency (Vmax2 / Km2 )
d 103.7 56.6
CPO to TCPy (Liver)
Km3 (mM) 627.90 6 165.00 660.70 6 167.00
In vitro Vmax3c (nmol / min / mg microsomal protein) 37.98 6 4.33 111.90 6 12.51
In vitro Catalytic efficiency (Vmax3c / Km3 )
ab 60.5 169.4
In vivo scaled Vmax3 (mmol / h / kg liver)
c 72922 6 8314 214848 6 24019
In vivo scaled Catalytic efficiency (Vmax3 / Km3 )
d 116.1 325.2
CPO to TCPy (Blood)
Km4 (mM) 75 75
Vmax4c (mmol / h / kg
0.75 body weight) 4.4 4.4
Catalytic efficiency (Vmax4c / Km4 )
e 0.05867 0.05867
Vmax4 (mmol / h)
f 106.48 93.28
Catalytic efficiency (Vmax4 / Km4 )
g 1.41973 1.24373
aml / min / mg microsomal protein
bVmaxc /Km *1000
cVmax ¼ Vmaxc / 1000* 60 * 32 *1000 , where the 32 is the scaling factor to scale the Vmaxc from nmol/min/mg microsomal protein to nmol/min/g liver, 1000 is for changing
unit from nmol to mmol, the 60 is for changing the unit from min to h and 1000 is for changing the unit from g to kg (liver).
dl / h / kg liver
el / h / kg0.75 body weight
fVmax4 (mmol/h/kg liver) ¼ Vmax4c * body weight 0.75, the body weight could be either the Caucasian body weight (70 kg) or the Chinese body weight (58.5kg)
gl / h
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for fa. Figure 9 also presents available experimental data for
in vivo CPF dose-dependent inhibition of AChE (solid circle/
unfilled square). These results reveal that predicted in vivo
dose-response curves for RBC AChE inhibition in the Caucasian
population were comparable with reported in vivo data (EPA,
1999; Timchalk et al., 2002), with the best fit obtained for an fa of
0.462. Data for Chinese subjects for further evaluation of the
predicted dose-response curves were not available.
From the results presented in Figure 9, it follows that in the
Chinese population similar AChE inhibition is reached at a 4- to
7-fold higher dose than in the Caucasian population. This indi-
cates that the Chinese population is less sensitive to CPF-
mediated AChE inhibition and CPF-related adverse effects than
the Caucasian population. Analysis of the differences in the ki-
netics reveals that this is mainly due to an approximately 4.5-
fold less efficient bioactivation of CPF to CPO combined with a
2.8-fold more efficient detoxification of CPO (Table 2).
Defining a point of departure for risk assessment. In a final step, the
predicted dose-response curves were used to derive a POD for
risk and safety assessment of CPF. To this end, the ED result-
ing from 10% or 20% inhibition of RBC AChE was derived from
the dose-response curves for both the Caucasian and Chinese
population, and was divided by 3 to obtain PODs that would
be comparable with BMDL or NOAEL values used as PODs in
previous risk assessments (BfR, 2012; EFSA, 2014; Fan, 2014;
Koshlukova and Reed, 2014). A 20% inhibition of AChE has
been defined before by EFSA to obtain a suitable POD to define
the acute reference dose for CPF (EFSA, 2014) whereas EPA in
its risk assessment of CPF established a BMDL10 resulting in
Figure 3. Comparison of the concentration-dependent rate of conversion of (A) CPF to CPO, (B) CPF to TCPy, and (C) CPO to TCPy, in incubations with Caucasian (solid
squares) and Chinese (solid circles) liver microsomes. Results represent data from 3 independent experiments and are presented as mean6SEM.
Figure 4. Comparison of PBK model-predicted and experimentally determined time-dependent (A) cumulative urinary excretion of TCPy and (B) blood concentrations
of TCPy in Caucasian volunteers upon oral administration of 0.5 mg CPF/kg bw (Nolan et al., 1984). The simulations were performed using an fa equal to 0.70, and either
Vd¼ 5.53 l (solid line) or Vd¼15 l (cross line), whereas the squares represent the values from the human volunteer study (Nolan et al., 1984).
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10% RBC AChE inhibition as POD (BfR, 2012; Fan, 2014;
Koshlukova and Reed, 2014). More recently, EPA indicated that
10% RBC AChE inhibition may not be adequately protective for
human health because several studies suggested that adverse
effects could occur even at lower levels of RBC AChE inhibition
(EPA, 2016).
In Figure 10, the obtained PODs for CPF are compared with
the POD established by EFSA based on 20% RBC AChE inhibition
in pups (EFSA, 2014) and the BMDL10 defined by EPA (BfR, 2012;
Fan, 2014; Koshlukova and Reed, 2014). The values are summa-
rized in Supplementary Data III to also specify the influence of
the fa on the values obtained. The comparison reveals that the
predicted PODs derived in the present study using the PBK
model–based reverse dosimetry are comparable with the PODs
defined by EFSA and EPA. The reported reference value of
0.5 mg/kg bw reported by EFSA (2014) is (depending on the fa
value) 0.6 to 1.8-fold higher compared with the predicted ED20/3
value for Caucasians and is 0.1 to 0.3-fold higher compared with
the predicted ED20/3 value for the Chinese population. When
compared with the EPA reported BMDL10 of 0.36 mg/kg bw (BfR,
2012; Fan, 2014; Koshlukova and Reed, 2014), the predicted ED10/
3 values for the Caucasian and the Chinese population are 1.3 to
4.3-fold lower and 0.2 to 0.8-fold higher, respectively, indicating
an interethnic variation, with values for the Chinese population
being approximately 5- to 6-fold higher than those for the
Caucasians, reflecting the lower sensitivity of the Chinese
population.
DISCUSSION
The aim of the present study was to investigate the intereth-
nic differences in kinetics, biomarker formation, and in vivo
RBC AChE inhibition for CPF in the Chinese and the
Caucasian population. To this end, CPF PBK models were de-
veloped for the Chinese and the Caucasian population and
subsequently used for the prediction of time- and dose-
dependent interethnic differences in kinetics and biomarker
formation as well as for reverse dosimetry to translate CPO
concentration-dependent data on inhibition of RBC AChE to
in vivo dose-response curves for CPF-induced inhibition of
RBC AChE.
The results obtained revealed a marked interethnic differ-
ence in toxicokinetics of CPF, with CYP450-mediated bioactiva-
tion to CPO being lower in Chinese, but PON1-mediated
detoxification of CPO being higher in Chinese, resulting in
higher predicted blood Cmax values for the toxic metabolite CPO
in the Caucasian than in the Chinese population at similar dose
levels (Figure 8A). This interethnic difference in toxicokinetics
of CPF may be related to differences between the ethnic groups
in the frequency of different alleles of the relevant CYP2B6,
CYP2C19, CYP3A4, and PON1 enzymes. For example, lower fre-
quencies for 2 CYP2B6 single-nucleotide polymorphisms (SNPs)
have been observed in the Chinese population (Guan et al.,
2006), SNPs that were shown to result in a relatively higher cata-
lytic efficiency for 7-ethoxy-4-trifluoromethylcoumarin O-dee-
thylation (substrate of CYP2B6) compared with wild type (Guan
et al., 2006; Jinno et al., 2003), suggesting that the Chinese popu-
lation might be less efficient in CYP2B6-catalyzed CPO forma-
tion than the Caucasian. Besides, it has been documented that
the catalytic efficiency for hydroxylation of the CYP2B6 sub-
strate bupropion by Chinese microsomes was 1.8-fold lower
than that for Caucasian microsomes (Yang et al., 2012).
Moreover, Barter et al. (2013) reported that the hepatic abun-
dance of CYP2C19 is only 8 pmol/mg in Chinese but 14 pmol/
mg in Caucasian, and the frequency of CYP2C19 poor metabo-
lizers is 13% in Chinese but only 2.4% in Caucasian. In addition,
it has been reported that PON1R192 hydrolyses CPO faster than
PON1Q192 (Ali and Chia, 2008; Eyer et al., 2009; Mutch et al.,
2007), so that a higher efficiency of CPO hydrolysis in the
Chinese population could be due to a relatively higher fre-
quency of the RR genotype in the Chinese. To our knowledge,
no comparison of genotype frequency of hepatic PON1 among
these 2 races has been reported, but a study by Ali and Chia
(2008) showed that Chinese have a higher RR genotype fre-
quency (33%) of plasma PON1 than Caucasians (8.7%). Because
plasma PON1 activity may result from release of the enzyme
from the liver (Ali and Chia, 2008), similar differences might be
expected in liver PON1 activity.
Evaluation of the developed PBK model against literature
data available on cumulative urinary elimination of TCPy and
blood Cmax of TCPy (Bouchard et al., 2005; Nolan et al., 1984;
Timchalk et al., 2002), indicated that the model was highly sen-
sitive to the fa. However, when taking the fa reported in the re-
spective studies into account revealed that the defined PBK
model was able to adequately predict the kinetics of CPF in the
human body. In subsequent steps the PBK models were used to
evaluate interethnic variation in biomarker formation and tox-
icity of CPF.
The prediction of cumulative urinary TCPy elimination,
which often used as a biomarker for CPF exposure, revealed an
Figure 5. Comparison of PBK model-predicted and experimentally determined time-dependent (A) cumulative urinary excretion of TCPy (Lu et al., 2009; Timchalk et al.,
2002) and (B) blood concentrations of TCPy in Caucasian volunteers upon oral administration of 0.5 mg CPF/kg bw (Timchalk et al., 2002). The simulations were per-
formed using fa¼0.224, and either Vd¼5.53 l (solid line) or Vd¼15 l (cross line), whereas the squares symbols represent the values from the human volunteer study
(Timchalk et al., 2002).
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around 2-fold lower cumulative TCPy elimination in the
Chinese than the Caucasian when they were exposed to the
same CPF dose level (Figure 8D). In other words, to reach a simi-
lar urinary TCPy elimination as the Caucasian, the correspond-
ing dose level of CPF exposure should be 1.3- to 5-fold higher in
the Chinese (Figure 8D). These results imply that when using
urinary TCPy elimination as a biomarker for the CPF exposure of
the Chinese population, dose levels will be relatively underesti-
mated for the Chinese population if these interethnic differen-
ces are not taken into account.
The consequences of interethnic differences in CPF kinetics
for its potential toxicity for Chinese and Caucasians were also
investigated using PBK modeling-facilitated reverse dosimetry.
To that end, the CPO concentration-dependent curve for RBC
AChE inhibition (Eyer et al., 2009) was translated to in vivo dose-
response curves for CPF-mediated RBC AChE inhibition for both
ethnic groups. The data thus obtained for the Caucasian
matched with the available in vivo human data available for this
ethnic group (Figure 9). This further validates the developed-
CPF PBK models and also provides support for the in vitro-PBK
model-facilitated reverse dosimetry approach to obtain in vivo
dose-response curves suitable for defining PODs for risk assess-
ment. In line with the differences between the ethnic groups in
formation and detoxification of the toxic CPO metabolite, the
obtained in vivo dose-response curves predicted CPF to be 4- to
7-fold more toxic for the Caucasian than for the Chinese popu-
lation. This was also reflected by the ED10/20 and ED10/20/3 values
derived from the predicted dose-response curves, being 5- to 6-
fold higher for the Chinese than the Caucasian population.
Important to note as well is that the predicted-PODs obtained
from the present study matches relatively well with the PODs
defined previously by both EFSA and EPA in their risk assess-
ment of CPF (BfR, 2012; EFSA, 2014; Fan, 2014; Koshlukova and
Reed, 2014).
Figure 6. Comparison of PBK model-predicted and experimentally determined time-dependent cumulative urinary excretion of TCPy at an oral dose of (A) 0.5 mg CPF/
kg bw, (C) 1.0 mg CPF/kg bw, and (E) 2 mg CPF/kg bw, and of PBK model predicted and experimentally determined blood concentration of TCPy at an oral dose of (B)
0.5 mg CPF/kg bw, (D) 1 mg CPF/kg bw, and (F) 2 mg CPF/kg bw. The simulations were performed using fa¼0.22, and either Vd¼5.53 l (solid line) or Vd¼ 15 l (cross line),
whereas the squares represent the valued took from Bouchard et al. (2005) which originally from Brzak (2000).
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Although the outcomes of our predictions are considered
adequate, the limitations of the approach presented should be
considered as well. Thus, it is of importance to mention that
the CPO concentration-response curve for RBC AChE inhibition
used in the current study was based on data reported by Eyer
et al. (2009), obtained with blood samples from Sri Lankan
patients with acute CPF poisoning (Eyer et al., 2009). In the
present study, we assumed that a similar CPO concentration-
dependent RBC AChE inhibition would occur in the Chinese
and Caucasian individuals, which implies that interethnic dif-
ferences in AChE sensitivity (if existing) are not (yet) taken
into account. However, given the similar primary and tertiary
structure of the AChE, it seems likely that interethnic differen-
ces in toxicodynamics may be limited, so that the differences
Figure 7. Sensitivity analysis representing the influence of model parameters on the predicted blood Cmax of CPO in the Caucasian and the Chinese population at a
dose of (A) 0.5 mg CPF/kg bw and (B) 180 mg CPF/kg bw. The parameters are stand for bw¼body weight, VLc¼ fraction of liver tissue, VSc¼ fraction of slowly perfused
tissue (bone, skin, and muscle), QC¼ cardiac output, QLc¼ fraction of blood flow to liver, QRc¼ fraction of blood flow to richly perfused tissue, QSc¼ fraction of blood
flow to slowly perfused tissue (bone, skin, and muscle), PSCPO¼ slowly perfused tissue/blood partition coefficient of CPO, MPL¼ scaling factor of human liver micro-
some, ka¼absorption constant, fa¼ fractional absorption, Vmax1c¼maximum rate of conversion from CPF to CPO, Km1¼kinetic constant for conversion from CPF to
CPO, Vmax2c¼maximum rate of conversion from CPF to TCPy, Km2¼kinetic constant for conversion from CPF to TCPy, Vmax3c¼maximum rate of conversion from CPO
to TCPy, Km3¼kinetic constant for conversion from CPO to TCPy.
Figure 8. Predicted (A) dose-dependent Cmax of CPO (B) time-dependent cumulative urinary excretion of TCPy at a dose of 0.5 mg CPF/kg bw, (C) time-dependent cumu-
lative urinary excretion of TCPy at a dose of 180 mg CPF/kg bw, and (D) dose-dependent cumulative urinary excretion of TCPy. All presented for both the Caucasian
(solid line) and Chinese (dash line) population, with fa¼0.224 at 24 h (thin solid/dashed line, for (D) only) and 72 h (thick solid/dashed line, for (D) only), respectively
(Timchalk et al., 2002).
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in toxicokinetics, as defined in the present study, may have
the largest influence on interethnic differences in toxicity.
Besides, because the values of kinetic parameters (Vmax4c and
Km4 in vitro) for PON1-mediated CPO hydrolysis in blood for
the Chinese are not available and Chinese plasma samples
were not commercially available, this Vmax4c in mmol/h for the
Chinese population was defined by multiplying the value
reported by Mosquin et al. (2009) in mmol/h/kg bw0.75 with the
Chinese average body weight 0.75, whereas Km4 was kept
unchanged. It is important to mention that based on the sen-
sitivity analysis, the impact of Vmax4c and Km4 on the pre-
dicted maximum blood concentration of CPO appeared to be
quite low (the SCs amount to a value of <0.01 data not
shown), which indicates that the impact of PON1-mediated
CPO hydrolysis in blood on the predicted maximum blood
concentration of CPO appears to be limited if not negligible.
This is supported by the fact that a 10-fold change in either
Vmax4c or Km4 in the Chinese model did not affect the pre-
dicted maximum blood concentration of CPO (Supplementary
Data IV).
In conclusion, our developed-CPF PBK models together
with reverse dosimetry are capable of predicting the in vivo ki-
netics and biomarker characteristics of CPF as well as CPF ex-
posure related RBC AChE inhibition in human in a
quantitative way. By developing the model for both the
Chinese and Caucasian population, insight was obtained in
the ethnic-related variation in these parameters. The observed
interethnic variation in the derived PODs for the 2 populations
may be caused by the racial variation in hepatic patterns of
the enzymes preferably involved in CPF bioactivation and de-
toxification, in particular CYP2B6 and PON1, respectively. This
variation in enzymes involved may be related to variation in
the frequency of relevant SNPs between the Chinese and
Caucasian population (Ali and Chia, 2008; Guan et al., 2006;
Lamba et al., 2003; ). Altogether, it is concluded that the inter-
ethnic variation in kinetics of CFP may affect both its
biomarker-based exposure assessment and its toxicity and
risk assessment, and the developed-CPF PBK models are able
to facilitate characterization and quantification of these inter-
ethnic differences.
Figure 9. Predicted in vivo dose-dependent RBC AChE inhibition upon CPF exposure for the Caucasian (solid line) and Chinese (dash line) population as well as reported
data (solid circles/unfilled squares) (EPA, 1999; Timchalk et al., 2002) using (A) fa¼0.224 (Timchalk et al., 2002), (B) fa¼0.46, and (C) fa¼0.70 (Nolan et al., 1984). The solid
circles represent the in vivo data from humans upon oral administration of 0.5 mg CPF/kg bw, 1 mg CPF/kg bw, and 2 mg CPF/kg bw (EPA, 1999), and the black unfilled
square represents in vivo data from Timchalk et al. (2002) in human exposed to 2 mg CPF/kg bw.
Figure 10. Comparison of the predicted and reported POD values by EFSA (2014) and
EPA (BfR, 2012; Fan, 2014; Koshlukova and Reed, 2014) for CPF risk assessment in hu-
man. The Y-axis represents the label for the corresponding box plot on the right. The
ED10 or ED20 values represent the predicted effective dose (ED) resulting in 10% or 20%
RBC AChE inhibition for the respective populations. The left, middle, and right line in
each box plot presents the ED value derived from fa equal to 0.7, 0.462, and 0.224, re-
spectively. The ED10/3 or ED20/3 values represent PODs derived from these ED values,
acknowledging that a BMDL (a lower confidence bound of the BMD) would be ac-
cepted as the POD for setting safe levels of exposure when it would be not more than
3-fold lower than the BMD, the dose level resulting in 10% or 20% effect above back-
ground level, and thus comparable to the ED. Both ED10 and ED20 are presented be-
cause the cutoff value to set the POD for AChE may be higher than the default of 10%.
In this way the predicted values can be compared with the EFSA POD (set at 20% ef-
fect level) and EPA POD (set at 10% effect level) (BfR, 2012; Fan, 2014; Koshlukova and
Reed, 2014). The dashed line in the plot is separating the results for 20% and 10% ef-
fect for RBC AChE inhibition.
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online.
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